Literature DB >> 17988462

Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis.

Tsadik T Abraham1, Ross H Lowe, Stephane O Pirnay, William D Darwin, Marilyn A Huestis.   

Abstract

A sensitive and specific method for extraction and quantification of Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC), and 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in human urine was developed and fully validated. To ensure complete hydrolysis of conjugates and capture of total analyte content, urine samples were hydrolyzed by two methods in series. Initial hydrolysis was with Escherichia coli beta-glucuronidase (Type IX-A) followed by a second hydrolysis utilizing 10N NaOH. Specimens were adjusted to pH 5-6.5, treated with acetonitrile to precipitate protein, and centrifuged, and the supernatants were subjected to solid-phase extraction. Extracted analytes were derivatized with BSTFA and quantified by gas chromatography-mass spectrometry with electron impact ionization. Standard curves were linear from 2.5 to 300 ng/mL. Extraction efficiencies were 57.0-59.3% for THC, 68.3-75.5% for 11-OH-THC, and 71.5-79.7% for THCCOOH. Intra- and interassay precision across the linear range of the assay ranged from 0.1 to 4.3% and 2.6 to 7.4%, respectively. Accuracy was within 15% of target concentrations. This method was applied to the analysis of urine specimens collected from individuals participating in controlled administration cannabis studies, and it may be a useful analytical procedure for determining recency of cannabis use in forensic toxicology applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988462      PMCID: PMC2689549          DOI: 10.1093/jat/31.8.477

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  32 in total

1.  Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.

Authors:  Thomas Nadulski; Fritz Pragst; Gordon Weinberg; Patrik Roser; Martin Schnelle; Eva-Maria Fronk; Andreas Michael Stadelmann
Journal:  Ther Drug Monit       Date:  2005-12       Impact factor: 3.681

2.  The detection of Delta9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THCA) in whole blood using two-dimensional gas chromatography and EI-mass spectrometry.

Authors:  Rodger D Scurlock; Greg B Ohlson; David K Worthen
Journal:  J Anal Toxicol       Date:  2006-05       Impact factor: 3.367

3.  Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

Authors:  D R Blake; P Robson; M Ho; R W Jubb; C S McCabe
Journal:  Rheumatology (Oxford)       Date:  2005-11-09       Impact factor: 7.580

4.  Simultaneous analysis of the Delta9-THC metabolites 11-nor-9-carboxy-Delta9-THC and 11-hydroxy-Delta9-THC in meconium by GC-MS.

Authors:  Rebecka Coles; Thomas T Clements; Gordon J Nelson; Gwendolyn A McMillin; Francis M Urry
Journal:  J Anal Toxicol       Date:  2005-09       Impact factor: 3.367

Review 5.  Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol.

Authors:  M A Huestis
Journal:  Handb Exp Pharmacol       Date:  2005

6.  Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.

Authors:  Thomas Nadulski; Frank Sporkert; Martin Schnelle; Andreas M Stadelmann; Patrik Roser; Tom Schefter; Fritz Pragst
Journal:  J Anal Toxicol       Date:  2005 Nov-Dec       Impact factor: 3.367

Review 7.  The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection.

Authors:  R Mechoulam; L Hanu
Journal:  Pain Res Manag       Date:  2001       Impact factor: 3.037

8.  Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.

Authors:  D T Wade; P M Makela; H House; C Bateman; P Robson
Journal:  Mult Scler       Date:  2006-10       Impact factor: 6.312

9.  delta 9-THC metabolites in meconium: identification of 11-OH-delta 9-THC, 8 beta,11-diOH-delta 9-THC, and 11-nor-delta 9-THC-9-COOH as major metabolites of delta 9-THC.

Authors:  M A ElSohly; S Feng
Journal:  J Anal Toxicol       Date:  1998 Jul-Aug       Impact factor: 3.367

10.  Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine.

Authors:  P M Kemp; I K Abukhalaf; J E Manno; B R Manno; D D Alford; M E McWilliams; F E Nixon; M J Fitzgerald; R R Reeves; M J Wood
Journal:  J Anal Toxicol       Date:  1995-09       Impact factor: 3.367

View more
  18 in total

1.  Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Authors:  David M Schwope; Erin L Karschner; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-11       Impact factor: 8.327

2.  Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry.

Authors:  Karl B Scheidweiler; Nathalie A Desrosiers; Marilyn A Huestis
Journal:  Clin Chim Acta       Date:  2012-07-06       Impact factor: 3.786

3.  Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry.

Authors:  David M Schwope; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2011-07-05       Impact factor: 4.142

4.  Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search.

Authors:  Ariane Wohlfarth; Karl B Scheidweiler; Xiaohong Chen; Hua-fen Liu; Marilyn A Huestis
Journal:  Anal Chem       Date:  2013-03-18       Impact factor: 6.986

5.  Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine.

Authors:  Mateus M Bergamaschi; Allan Barnes; Regina H C Queiroz; Yasmin L Hurd; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-03-15       Impact factor: 4.142

6.  Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.

Authors:  Garry Milman; Allan J Barnes; Ross H Lowe; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2010-01-04       Impact factor: 4.759

7.  Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Authors:  Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

8.  In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis.

Authors:  Nathalie A Desrosiers; Dayong Lee; Karl B Scheidweiler; Marta Concheiro-Guisan; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-12-01       Impact factor: 4.142

9.  Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

10.  Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

Authors:  Ross H Lowe; Tsadik T Abraham; William D Darwin; Ronald Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2009-07-23       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.